In Canada, the acute ischemic stroke drugs market generated approximately USD 265 million in 2024 and is projected to grow at a compound annual growth rate of about 5.8% through the forecast period.One of the primary drivers is the rising incidence of cardiovascular and chronic diseases including hypertension, diabetes, and obesity among its aging population, which directly increases stroke event rates and the demand for thrombolytic and anticoagulant therapeuticsCanadian healthcare policy, supported by federal and provincial health agencies, also actively emphasizes chronic disease management and stroke care strategies, bolstering adoption rates of AIS interventions
TABLE - Canada Acute Ischemic Stroke Drugs Market Size & Forecast By Drug Class 2021-2033
Drug Class | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Thrombolytics | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Anticoagulant | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Antiplatelet | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Neuroprotective Agent | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis